Affiliation:
1. Department of Medical Microbiology, Medical University of Warsaw, Chalubinskiego 5 Str., 02-004 Warsaw, Poland
Abstract
Abstract:
Among antiviral drugs, the vast majority targets only one or two related viruses. The conventional model, one virus - one drug, significantly limits therapeutic options. Therefore, in the strategy of controlling viral infections, there is a necessity to develop compounds with pleiotropic effects. Favipiravir (FPV) emerged as a strong candidate to become such a drug. The aim of the study is to present up-to-date information on the role of favipiravir in the treatment of viral respiratory infections. The anti-influenza activity of favipiravir has been confirmed in cell culture experiments, animal models, and clinical trials. Thoroughly different - from the previously registered drugs - mechanism of action suggests that FVP can be used as a countermeasure for the novel or re-emerging influenza virus infections. In recent months, favipiravir has been broadly investigated due to its potential efficacy in the treatment of COVID-19. Based on preclinical and clinical studies and a recently published meta-analysis it seems that favipiravir may be a promising antiviral drug in the treatment of patients with COVID-19. FPV is also effective against other RNA respiratory viruses and may be a candidate for the treatment of serious infections caused by human rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza viruses and hantavirus pulmonary syndrome.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine
Reference94 articles.
1. Shiraki K.; Daikoku T.; Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020,209
2. Łagocka R.; Dziedziejko V.; Kłos P.; Pawlik A.; Favipiravir in therapy of viral infections. J Clin Med 2021,10(2),273
3. Report on the deliberation results March 4, 2014 evaluation and licensing division, pharmaceutical and food safety bureau ministry of health, labour and welfare. Available from: [Accessed on 12th Nov, 2020].2014
4. Clinical Trials. US National Library of Medicine Available from: [Accessed on 21st Mar 2021].
5. Furuta Y.; Takahashi K.; Shiraki K.; Sakamoto K.; Smee D.F.; Barnard D.L.; Gowen B.B.; Julander J.G.; Morrey J.D.; T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009,82(3),95-102
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献